Critical aspects of the Bayesian approach to phase I cancer trials | Zendy

Neuenschwander Beat | Zendy; Branson Michael | Zendy; Gsponer Thomas | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Premium

Critical aspects of the Bayesian approach to phase I cancer trials

Author(s) -

Neuenschwander Beat,

Branson Michael,

Gsponer Thomas

Publication year - 2008

Publication title -

statistics in medicine

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 1.996

H-Index - 183

eISSN - 1097-0258

pISSN - 0277-6715

DOI - 10.1002/sim.3230

Subject(s) - bayesian probability , computer science , clinical trial , maximum tolerated dose , prior information , bayesian inference , cancer , data mining , machine learning , econometrics , artificial intelligence , medicine , mathematics

The Bayesian approach to finding the maximum‐tolerated dose in phase I cancer trials is discussed. The suggested approach relies on a realistic dose–toxicity model, allows one to include prior information, and supports clinical decision making by presenting within‐trial information in a transparent way. The modeling and decision‐making components are flexible enough to be extendable to more complex settings. Critical aspects are emphasized and a comparison with the continual reassessment method (CRM) is performed with data from an actual trial and a simulation study. The comparison revealed similar operating characteristics while avoiding some of the difficulties encountered in the actual trial when applying the CRM. Copyright © 2008 John Wiley & Sons, Ltd.

This content is not available in your region!

Continue researching here.

Having issues? You can contact us here

Accelerating Research